These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 29732009)

  • 21. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.
    Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations.
    Kim TJ; Lee CT; Jheon SH; Park JS; Chung JH
    Ann Thorac Surg; 2016 Feb; 101(2):473-80. PubMed ID: 26454747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies.
    Stoyanova R; Pollack A; Takhar M; Lynne C; Parra N; Lam LL; Alshalalfa M; Buerki C; Castillo R; Jorda M; Ashab HA; Kryvenko ON; Punnen S; Parekh DJ; Abramowitz MC; Gillies RJ; Davicioni E; Erho N; Ishkanian A
    Oncotarget; 2016 Aug; 7(33):53362-53376. PubMed ID: 27438142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape.
    Yamamoto S; Maki DD; Korn RL; Kuo MD
    AJR Am J Roentgenol; 2012 Sep; 199(3):654-63. PubMed ID: 22915408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
    Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
    PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
    Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
    J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Input of molecular analysis in medical management of primary brain tumor patients.
    Idbaih A; Duran-Peña A; Bonnet C; Ducray F
    Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
    Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR
    Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiogenomics and IR.
    Lam A; Bui K; Hernandez Rangel E; Nguyentat M; Fernando D; Nelson K; Abi-Jaoudeh N
    J Vasc Interv Radiol; 2018 May; 29(5):706-713. PubMed ID: 29551544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of cell-free circulating tumor DNA testing for lung cancer.
    Santarpia M; Karachaliou N; González-Cao M; Altavilla G; Giovannetti E; Rosell R
    Biomark Med; 2016; 10(4):417-30. PubMed ID: 26974841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer.
    Martin-Gonzalez P; Crispin-Ortuzar M; Rundo L; Delgado-Ortet M; Reinius M; Beer L; Woitek R; Ursprung S; Addley H; Brenton JD; Markowetz F; Sala E
    Insights Imaging; 2020 Aug; 11(1):94. PubMed ID: 32804260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological markers in lung cancer: A clinician's perspective.
    Tufman A; Huber RM
    Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.
    Even AJG; Reymen B; La Fontaine MD; Das M; Jochems A; Mottaghy FM; Belderbos JSA; De Ruysscher D; Lambin P; van Elmpt W
    Acta Oncol; 2017 Nov; 56(11):1591-1596. PubMed ID: 28840770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a case-control study.
    Song SE; Shin SU; Moon HG; Ryu HS; Kim K; Moon WK
    Breast Cancer Res Treat; 2017 Apr; 162(3):559-569. PubMed ID: 28185146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
    Quéré G; Descourt R; Robinet G; Autret S; Raguenes O; Fercot B; Alemany P; Uguen A; Férec C; Quintin-Roué I; Le Gac G
    BMC Cancer; 2016 Mar; 16():210. PubMed ID: 26968843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
    Tixier F; Vriens D; Cheze-Le Rest C; Hatt M; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP; Visvikis D
    J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging genomics in cancer research: limitations and promises.
    Bai HX; Lee AM; Yang L; Zhang P; Davatzikos C; Maris JM; Diskin SJ
    Br J Radiol; 2016; 89(1061):20151030. PubMed ID: 26864054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.